Klaria’s business concept is based on developing and commercialising innovative products with clear competitive benefits in the therapeutic fields of migraine and cancer-related pain. Klaria received € 2M from the SME Instrument HORIZON 2020, phase 2.
“Working with GAEU has provided the necessary structure and balance to our application. Their experience in emphasizing and bringing out the broader potential of our innovation and expressing that potential in clear text has been the most valuable part of our interaction. Navigation of the H2020 application process is complex, but with the help of GAEU, Klaria has been able to focus on bringing out key points in the broad potential of our innovation and critically, will aid in our presentation of our company in discussions with investors and shareholders outside of the context of H2020.”
Dr. Scott Boyer, CEO, Klaria